BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
Want to see BIOA full AI Analyst Report?
Top Page
BioAge Labs, Inc.
(NASDAQ:BIOA)
Select Model
Select Model
Rating:51Neutral
Price Target:
$18.50
▲(0.05% Upside)
Action:ReiteratedDate:03/25/26
BIOA scores 51 mainly due to heavy losses and significant cash burn despite early revenue growth and low leverage. Technical indicators add modest near-term caution with price below key short-term averages. Offsetting these, recent positive clinical/pipeline updates and balance-sheet strengthening via financing provide supportive optionality.
Positive Factors
Strong cash runway
An upsized $132.3M follow-on offering and year-end cash/securities of $285.1M materially reduce near-term financing risk and provide multi-year funding. This runway allows BioAge to execute planned Phase 2/1b/2a studies and advance multiple programs without immediate capital pressure.
Negative Factors
High cash burn
Operating and free cash flow of roughly -$82M in 2025 indicate substantial ongoing cash burn to support R&D and clinical programs. Persistently negative cash generation increases dependency on financings or partner income and elevates execution risk if trial timelines or outcomes slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway
An upsized $132.3M follow-on offering and year-end cash/securities of $285.1M materially reduce near-term financing risk and provide multi-year funding. This runway allows BioAge to execute planned Phase 2/1b/2a studies and advance multiple programs without immediate capital pressure.
Read all positive factors
BioAge Labs, Inc. (BIOA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$748.10M
Dividend YieldN/A
Average Volume (3M)532.22K
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue GrowthN/A
EPS Growth-9.36%
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.72
Shares Outstanding44,397,816
10 Day Avg. Volume302,867
30 Day Avg. Volume532,223
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue47.06
Enterprise Value/Gross Profit47.42
Enterprise Value/Ebitda-5.14
Forecast
1Y Price Target
$53.33Price Target Upside188.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.68
Revenue Forecast (FY)$4.54M
BioAge Labs, Inc. Business Overview & Revenue Model
Company Description
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insi...
How the Company Makes Money
null...
BioAge Labs, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 8.99M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.99M | 0.00 | 0.00 | 0.00 |
| EBITDA | -92.78M | -68.58M | -55.90M | -39.35M |
| Net Income | -80.61M | -71.11M | -63.85M | -39.72M |
Balance Sheet | ||||
| Total Assets | 294.89M | 358.23M | 25.92M | 28.43M |
| Cash, Cash Equivalents and Short-Term Investments | 281.10M | 354.35M | 21.64M | 27.64M |
| Total Debt | 5.56M | 8.70M | 53.25M | 2.47M |
| Total Liabilities | 22.84M | 35.11M | 199.32M | 140.99M |
| Stockholders Equity | 272.05M | 323.13M | -173.40M | -112.56M |
Cash Flow | ||||
| Free Cash Flow | -82.35M | -51.89M | -37.53M | -36.28M |
| Operating Cash Flow | -81.63M | -51.52M | -37.36M | -36.18M |
| Investing Cash Flow | -95.22M | -366.00K | -266.00K | -103.00K |
| Financing Cash Flow | 11.47M | 381.20M | 34.94M | 2.50M |
BioAge Labs, Inc. Risk Analysis
BioAge Labs, Inc. disclosed 66 risk factors in its most recent earnings report. BioAge Labs, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioAge Labs, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $672.62M | 22.76 | -8.22% | ― | -15.72% | 1233.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $748.10M | -4.58 | -27.86% | ― | ― | -9.36% | |
49 Neutral | $61.34M | -4.80 | -199.09% | ― | -100.00% | 46.50% | |
48 Neutral | $190.01M | -9.61 | -182.11% | ― | 0.47% | -430.88% | |
48 Neutral | $140.75M | -16.52 | -46.40% | ― | 10.20% | 35.27% |
* Healthcare Sector Average
BIOA
BioAge Labs, Inc.
16.79
12.60
300.72%
IRWD
Ironwood Pharma
4.44
3.51
376.39%
LFCR
Lifecore Biomedical
5.26
-2.03
-27.85%
SXTC
China SXT Pharmaceuticals
2.07
-339.93
-99.39%
DERM
Journey Medical Corp
5.19
-1.84
-26.17%
IXHL
Incannex Healthcare Limited Sponsored ADR
4.55
0.57
14.29%
BioAge Labs, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
BioAge Highlights BGE-102 Progress and Financial Strength
Positive
Mar 24, 2026
BioAge Labs reported its full-year 2025 results and late-2025 operational milestones on March 24, 2026, highlighting strong progress for BGE-102, its oral, brain-penetrant NLRP3 inhibitor. Positive interim Phase 1 data in December 2025 and January...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.